Glut-1, HK-II, and PCNA expression are related to uptake of 18F-FDG uptake in lung cancer

Glut-1 plays a crucial role in determining FDG uptake in neuroendocrine (NE) lung tumors

Glut1 and HIF-1 alpha are highly expressed in non-small cell lung carcinoma, and their expressions are associated with tumor differentiation and clinical stage.

GLUT-1 is expressed in approximately half of the pulmonary neuroendocrine carcinomas and shows a strong correlation with neuroendocrine differentiation/grade

SLC2A1 polymorphism was significantly associated with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-uptake in combination with the apurinic/apyimidinic endonuclease Asp148Glu (T>G) polymorphism in the squamous cell type of non-small-cell lung cancer.

high expression in lung adenocarcinoma is associated with a poor survival

GLUT1 mRNA levels were detected by reverse transcription-polymerase chain reaction (RT-PCR) in SurePath(TM) liquid-based cytology bronchial brushing specimens from patients with lung cancer and benign lung disease.

High GLUT1 expresssion is associated with lung adenocarcinoma invasiveness.

GLUT-1/KOC do not differentiate malignant mesotheliomas from pulmonary adenocarcinomas but can be useful in differentiating reactive mesothelial hyperplasia from malignant mesothelioma and lung adenocarcinoma.

Low glut-1 expression is associated with poor treatment response in small-cell lung cancer.

aerobic glycolysis and cell proliferation were down-regulated when GLUT1 gene expression was suppressed in lung adenocarcinoma cell lines with activating EGFR mutations

polymorphisms of SLC2A1 (rs3738514, rs4658, rs841844) were significantly related to overall toxicity of platinum-based chemotherapy in lung cancer patients

expression changes of E6 and E7 significantly promoted the protein expression of HIF-1alpha, the expression of both protein and mRNA of GLUT1, but had no effect on the expression of HIF-1alpha mRNA in lung cancer cells.

AKT inhibition blocks miR-124 silencing-induced AKT1/2, glucose transporter 1, hexokinase II activation, cell proliferation, and glycolytic or energy metabolism changes. In summary, this study demonstrated that miR-124 is able to inhibit proliferation, glycolysis, and energy metabolism, potentially by targeting AKT1/2-glucose transporter 1/hexokinase II in non-small cell lung cancer cells.

High levels of GLUT1 are associated with lung Adenocarcinoma.

genetic variation in GLUT1 is associated with Early-Stage Non-small Cell lung cancer.

A positive expression of GLUT1 significantly predicts a poor prognosis in lung cancer patients. GLUT1 may server as a helpful biomarker and a potential target for the treatment strategies of lung cancer.[review;meta-analysis]

low expression of S is associated with improved prognosis in non-small-cell lung cancer

High SLC2A1 expression was significantly ( p < 0.05) associated with a poor prognosis in stage I, II, and III subgroups using the Kaplan-Meier plotter. SLC2A1 is a promising biomarker that can be used to predict the prognosis of lung adenocarcinoma.

lung cancer cell subpopulations within the collective invasion pack have distinct metabolic requirements. Leader cells rely on active pyruvate dehydrogenase to sustain mitochondrial respiration whereas follower cells highly express GLUT1, which sustains an elevated level of glucose uptake required to maintain proliferation.

[Progress in the clinical application and correlation between glucose transporter-1 and (18)F-FDG PET/CT imaging for non-small cell lung cancer].